Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 1.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,841,969 shares of the company’s stock after acquiring an additional 218,025 shares during the period. Vanguard Group Inc.’s holdings in Amneal Pharmaceuticals were worth $117,548,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. JPMorgan Chase & Co. grew its stake in Amneal Pharmaceuticals by 149.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock worth $10,792,000 after purchasing an additional 777,568 shares in the last quarter. Barclays PLC boosted its stake in shares of Amneal Pharmaceuticals by 134.1% in the 3rd quarter. Barclays PLC now owns 296,384 shares of the company’s stock valued at $2,466,000 after buying an additional 169,756 shares during the period. State Street Corp grew its position in shares of Amneal Pharmaceuticals by 3.8% during the third quarter. State Street Corp now owns 3,514,721 shares of the company’s stock worth $29,242,000 after buying an additional 127,753 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth approximately $520,000. Finally, Geode Capital Management LLC raised its holdings in Amneal Pharmaceuticals by 11.1% in the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock valued at $31,511,000 after acquiring an additional 378,136 shares in the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the company from $9.00 to $12.00 in a report on Monday, February 24th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $10.80.

Insider Activity

In other news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the sale, the insider now directly owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.33 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Gautam Patel sold 80,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $8.14, for a total transaction of $651,200.00. Following the transaction, the director now directly owns 1,888,886 shares in the company, valued at $15,375,532.04. The trade was a 4.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,160,000 shares of company stock worth $43,113,200 over the last 90 days. 26.56% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Trading Down 3.1 %

NASDAQ AMRX opened at $6.99 on Wednesday. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -10.28 and a beta of 1.06. The business’s 50 day moving average is $8.26 and its two-hundred day moving average is $8.31. Amneal Pharmaceuticals, Inc. has a 12-month low of $5.18 and a 12-month high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). The company had revenue of $730.52 million during the quarter, compared to analysts’ expectations of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same quarter in the prior year, the business earned $0.14 EPS. Equities analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.